Avalere Health
An Inovalon Company
Services

Patient Engagement

Integrate Patient Voice

Patient engagement represents the nexus of patient experiences, motivations, and values— all significant keys to the changing healthcare system. Patient voices and behaviors are fundamental drivers to identifying providers, services, therapies, and products that patients value. Engaging patients and families increases their affinity for services and products. Avalere supports providers and plans seeking greater partnerships with industry stakeholders to implement patient engagement programs, such as disease education, adherence programs, and shared decision-making tools. We also partner with life sciences companies to integrate patient input early and often in the drug design and development process. We advise patient groups and foundations on how to best support the generation and dissemination of evidence surrounding patient and family engagement.

What's Your Challenge?

  • ​Comprehensive Patient and Family Engagement Strategy
  • ​Patient-Reported Outcome Measures
  • ​Patient-Centered Drug Research, Development, and Approval
  • ​Treatment Adherence

Complementary Products

Team

Meet a few of our experts ready to partner with you.

All Staff

Josh Seidman

Senior Vice President

Josh
Seidman

Josh Seidman, Senior Vice President, advises clients on health delivery and payment innovation with a focus on using information technology to guide value-based care models. He applies his background in quality, health IT and patient engagement to accountable care, delivery system transformation and new payment models.

Prior to joining Avalere, Josh was a Managing Director at Evolent Health, where he supported large delivery system clients in quality measurement and performance improvement around clinical transformation, patient engagement and population health management programs. Prior to that, Josh was a Director of Meaningful Use at the Department of Health and Human Services in the Office of the National Coordinator for Health Information Technology, and before that, the founding President of the Center for Information Therapy and Director of Measure Development at NCQA.

Josh holds a PhD and an MHS, Health Policy and Management from Johns Hopkins Bloomberg School of Public Health and a BA from Brown University. Josh currently serves as Immediate Past President of the Society for Participatory Medicine, and was a William B. Ziff Fellow for patient engagement with the Center for Advancing Health.

Nelly Ganesan

Director

Nelly
Ganesan

Nelly Ganesan, Director, advises clients on the implications of public reporting programs, use of quality measures, and the impact of quality improvement. Nelly also has special expertise in care models focused on CMS’ Triple Aim: Better Care, Better Health, and Lower Costs. 

Prior to joining Avalere, Nelly served as a Triple Aim Program Manager at the Institute for Healthcare Improvement. Nelly’s past work also highlights her interest in global and public health.

Nelly has a BS in Economics from the University of Oregon and a MPH in Epidemiology and International Health from Boston University.

Brenda Huneycutt

Vice President

Brenda
Huneycutt

Brenda Huneycutt, PhD, JD, MPH, Vice President in Avalere’s FDA Strategy and Regulatory Policy practice, advises clients on regulatory strategy and policy spanning drugs, biologics and diagnostics, and conducts due diligence assessments for clients looking to acquire or in-license products. Using her molecular biology research background, combined with her legal and public health policy training, Brenda helps clients translate technical information into clear descriptions for various audiences, and offers special expertise in regulatory strategy for FDA approval strategies involving accelerated and new pathways, including breakthrough therapy and orphan designations, and biosimilars and interchangeable biologics. 

Prior to joining Avalere, Brenda conducted research at the Genetics and Public Policy Center at Johns Hopkins University and was an Patent Attorney for Finnegan, LLP.

Brenda has a BA in Biology from the University of Delaware; a PhD in Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder; a JD from the George Washington University School of Law; and a MPH from Johns Hopkins Bloomberg School of Public Health.

Debleena Sengupta

Director

Debleena
Sengupta

Debleena Sengupta, PhD, RAC, Director, advises clients on FDA regulatory strategy and policy. She applies her research background in molecular biology and biochemistry, along with over ten years of regulatory experience helping clients with the development, approval and life cycle management of drug and biological products. Debleena has special expertise in both regulatory therapeutic area strategy and CMC, and has worked at brand and generic companies. She also has experience performing FDA regulatory due diligence.

Prior to joining Avalere, Debleena was an Associate Director at Forest Research Institute, providing regulatory affairs strategy and serving as the primary liaison between FDA and the company for a portfolio of CNS drugs. Prior to that, as Manager and Liaison, Global Regulatory Affairs, at Merck & Co. (formerly Schering Plough), she was responsible for the CMC content for a number of products registered in the European Union, as well as international drug filings and approvals.

Debleena has a PhD in Chemistry from Columbia University and a BS in Chemistry from Stanford. She also holds a Regulatory Affairs Certification (RAC).

« Back to Mobile Site